ER+ BREAST CANCER

Clinical trials for ER+ BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new ER+ BREAST CANCER trials appear

Sign up with your email to follow new studies for ER+ BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 11 Not yet recruiting 1 Not yet finished but already full! 3 Terminated 1

New cancer drug BBI-355 trial halted early – what we know

Disease control Terminated

This early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…

Matched conditions: ER+ BREAST CANCER

Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control

Last updated Jun 27, 2026 13:04 UTC

ER+ BREAST CANCER

Get alerted when new ER+ BREAST CANCER trials appear

New cancer drug BBI-355 trial halted early – what we know